Tohoku Innovation Capital

Future Ink Corporation, established in 2016 and based in Yonezawa, Japan, specializes in the development, manufacturing, and marketing of printed electronics and related products. The company offers an n-type organic semiconductor material that is soluble in organic solvents and produces printable film sensors that can be integrated into various designs. These sensors are designed to address everyday challenges faced by individuals, particularly the elderly, people with disabilities, and infants. Future Ink's devices provide critical information about users' well-being, helping them manage the invisible stresses of modern life and aiding in their overall vitality. In addition to manufacturing and selling optical and electronic devices, the company also engages in the design, prototyping, and development of medical equipment while offering services for evaluating electronic device characteristics and material performance.

Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, specializing in metabolomics technologies and solutions for drug discovery, diagnosis, and food production. The company offers a range of services, including metabolome analysis, global profiling, targeted assays, flux analysis, and lipidomics. It is recognized for its development of biomarkers, such as Phosphorylethanolamine, associated with major depressive disorder. The company addresses various applications in cancer metabolism, metabolic flux analysis, basic science, and nutrition. Additionally, it collaborates with the Institute for Advanced Biosciences and Keio University to enhance metabolome analysis technology. Founded in 2003, Human Metabolome Technologies plays a significant role in advancing research in pharmaceuticals, biotechnology, and food industries.